P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.

Detalles Bibliográficos
Autores principales: Tadmor, Tamar, Melamed, Guy, Alapi, Hilel, Gazit, Sivan, Patalon, Tal, Rokach, Lior
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429094/
http://dx.doi.org/10.1097/01.HS9.0000969512.94466.6d
_version_ 1785090627983114240
author Tadmor, Tamar
Melamed, Guy
Alapi, Hilel
Gazit, Sivan
Patalon, Tal
Rokach, Lior
author_facet Tadmor, Tamar
Melamed, Guy
Alapi, Hilel
Gazit, Sivan
Patalon, Tal
Rokach, Lior
author_sort Tadmor, Tamar
collection PubMed
description
format Online
Article
Text
id pubmed-10429094
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104290942023-08-17 P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS. Tadmor, Tamar Melamed, Guy Alapi, Hilel Gazit, Sivan Patalon, Tal Rokach, Lior Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429094/ http://dx.doi.org/10.1097/01.HS9.0000969512.94466.6d Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Tadmor, Tamar
Melamed, Guy
Alapi, Hilel
Gazit, Sivan
Patalon, Tal
Rokach, Lior
P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.
title P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.
title_full P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.
title_fullStr P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.
title_full_unstemmed P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.
title_short P652: IMPROVED SURVIVAL OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BETWEEN 1998-2022, INCLUDING THE ERA OF TARGET THERAPIES WITH BCL2 AND BTK INHIBITORS.
title_sort p652: improved survival of patients with chronic lymphocytic leukemia between 1998-2022, including the era of target therapies with bcl2 and btk inhibitors.
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429094/
http://dx.doi.org/10.1097/01.HS9.0000969512.94466.6d
work_keys_str_mv AT tadmortamar p652improvedsurvivalofpatientswithchroniclymphocyticleukemiabetween19982022includingtheeraoftargettherapieswithbcl2andbtkinhibitors
AT melamedguy p652improvedsurvivalofpatientswithchroniclymphocyticleukemiabetween19982022includingtheeraoftargettherapieswithbcl2andbtkinhibitors
AT alapihilel p652improvedsurvivalofpatientswithchroniclymphocyticleukemiabetween19982022includingtheeraoftargettherapieswithbcl2andbtkinhibitors
AT gazitsivan p652improvedsurvivalofpatientswithchroniclymphocyticleukemiabetween19982022includingtheeraoftargettherapieswithbcl2andbtkinhibitors
AT patalontal p652improvedsurvivalofpatientswithchroniclymphocyticleukemiabetween19982022includingtheeraoftargettherapieswithbcl2andbtkinhibitors
AT rokachlior p652improvedsurvivalofpatientswithchroniclymphocyticleukemiabetween19982022includingtheeraoftargettherapieswithbcl2andbtkinhibitors

Ejemplares similares